RUDN Journal of Medicine

Вестник Российского университета дружбы народов. Серия: Медицина

2313-02452313-0261

Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)

16637

10.22363/2313-0245-2017-21-2-171-183

Articles

Статьи

Research Article

ENDOVASCULAR INTERVENTION OF CORONARY ARTERY BYPASS GRAFT

ЭНДОВАСКУЛЯРНЫЕ ВМЕШАТЕЛЬСТВА НА ВЕНОЗНЫХ ШУНТАХ (обзор литературы)

Bazanov

I S

Базанов

И С

к.м.н., ФГБУ «3 ЦВКГ им. А.А. Вишневского» МО РФ

ba333333a@gmail.com

Ivanov

V A

Иванов

В А

konovalov_oe@rudn.university

Zharikov

S B

Жариков

С Б

konovalov_oe@rudn.university

Polyakov

I I

Поляков

И И

konovalov_oe@rudn.university

Tsymbal

E V

Цымбал

Е В

konovalov_oe@rudn.university

Musoev

T Ya

Мусоев

Т Я

konovalov_oe@rudn.university

Sitko

I G

Ситько

И Г

konovalov_oe@rudn.university

Lokshina

M V

Локшина

М В

konovalov_oe@rudn.university

3rd Central military clinical hospital N.A. Vishnevsky, Krasnogorsk, RussiaФГБУ «3 ЦВКГ им. А.А.Вишневского» МО РФ, Новый, Красногорский район, Россия

3rd Central military clinical hospital N.A. Vishnevsky, Krasnogorsk, RussiaРоссийский университет дружбы народов, Москва, Россия

RUDN University, Moscow, RussiaФГБУ «3 ЦВКГ им. А.А.Вишневского» МО РФ, Новый, Красногорский район, Россия

RUDN University, Moscow, RussiaРоссийский университет дружбы народов, Москва, Россия

GKB M. P. Konchalovsky, Moscow, RussiaГКБ им. М. П. Кончаловского, Москва, Россия

15122017

212

VOL 21, NO2 (2017)

ТОМ 21, №2 (2017)

17118309092017

2017

Bazanov I.S., Ivanov V.A., Zharikov S.B., Polyakov I.I., Tsymbal E.V., Musoev T.Y., Sitko I.G., Lokshina M.V.

Базанов И.С., Иванов В.А., Жариков С.Б., Поляков И.И., Цымбал Е.В., Мусоев Т.Я., Ситько И.Г., Локшина М.В.

http://creativecommons.org/licenses/by/4.0

https://journals.rudn.ru/medicine/article/view/16637

In the first year occlusion occurs 10-15% of coronary artery bypass graft in 10 years - 50%, which causes the resumption of anginal patients after CABG. One of the most effective and safe methods of treatment of these patients is recognized endovascular intervention artery bypass graft failure or inter-vention of native coronary artery. In contrast classical percutaneous coronary reconstructions, for which there exist algorithms endovascular treatment for minimizing intraoperative risk and achieving the best long term results, treatment of saphenous vein grafts (SVG) still remains a challenging clinical problem. This article is a summary review of the literature dedicated to endovascular interventions for myocardial revascularization on the coronary artery bypass graft in patient after CABG. Analysis of the research allowed us to draw conclusions about the tactics of endovascular treatment of patients with return of angina after CABG, as well as about the defeat of the saphenous vein grafts lesions for endovascular interventions, and to identify the technical features of the SVG stenting.

В ходе исследований установлено, что в течение первого года происходит окклюзия 10-15% шунтов, через 10 лет - 50%, что вызывает возобновление клиники стенокардии у пациентов после КШ. Одним из самых эффективных и безопасных методов лечения данных пациентов при-знается эндоваскулярная коррекция компроментированных шунтов либо восстановление нативного артериального русла. В отличие от классических чрескожных коронарных реконструкций, для кото-рых существуют алгоритмы эндоваскулярного лечения, способствующие минимизации интраопера-ционного риска и достижению наилучшего отдаленного результата, лечение аутовенозных шунтов (АВШ) до сих пор остается сложной клинической задачей. В данной статье приводиться краткий обзор литературных данных, посвященных эндоваскулярным вмешательствам на аутовенозных шунтах коронарных артерий. Анализ исследований позволил сделать выводы о тактике эндоваску-лярного лечения пациентов с возвратом стенокардии после КШ, а также о том, какие поражения венозных шунтов подходят для эндоваскулярных вмешательств, и выявить технические особен-ности стентирования шунтов.

stenting of saphenous vein graftstechnical features of PCI graftsembolic protection devices

стентирование венозных шунтовтехнические особенности ЧКВ шунтовустройства зашиты от дистальной эмболии

Abdel-Karim A. R., Da Silva M., Lichtenwalter C., et al. Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. Int J Cardiol. 2013;168(3):2468—2473. Epub 2013 Apr 3. 19.

Abdel-Karim A.R., Da Silva M., Lichtenwalter C., et al. Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial // Int J Cardiol. 2013;168(3):2468-2473. Epub 2013 Apr 3. 19.

Abdel-Karim A. R., Da Silva M. & Lichtenwalter C. Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. Int J Cardiol. 2013;168(3):2468—2473. Epub 2013 Apr 3. 6.

Abdel-Karim A.R., Da Silva M., Lichtenwalter C. Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomizedcontrolled trial // Int J Cardiol. 2013;168(3):2468-2473. Epub 2013 Apr 3. 6.

Ahmed J. M., Dangas G., Lansky A. J. Influence of gender on early and one-year clinical out-comes after saphenous vein graft stenting. Am J Cardiol. 2001;87(4):401—405. 11.

Ahmed J.M., Dangas G., Lansky A.J. Influence of gender on early and one-year clinical outcomes after saphenous vein graft stenting // Am J Cardiol. 2001;87(4):401-405. 11.

Aqel R., Zoghbi G. J., Hage F., Dell’Italia L. & Iskandrian A. E. Hemodynamic evaluation of coronary artery bypass graft lesions using fractional flow reserve. Catheter Cardiovasc Interv. 2008;72(4):479—485. 16.

Aqel R., Zoghbi G.J., Hage F., Dell’Italia L., Iskandrian A.E. Hemodynamic evaluation of coronary artery bypass graft lesions using fractional flow reserve // Catheter Cardiovasc Interv. 2008;72(4):479-485. 16.

De Bruyne B., Pijls N. H., Kalesan B., et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991—1001. 17.

De Bruyne B., Pijls N.H., Kalesan B., et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease // N Engl J Med. 2012;367(11):991-1001. 17.

Desai N. D., Cohen E. A., Naylor C. D. & Fremes S. E. A randomized comparison of radial-ar¬tery and saphenous-vein coronary bypass grafts. N Engl J Med. 2004;351(22):2302—2309. 2.

Desai N.D., Cohen E.A., Naylor C.D., Fremes S.E. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts // N Engl J Med. 2004;351(22):2302-2309. 2.

Dixon S. Saphenous vein graft protection in a distal embolic protection randomized trial. Pre-sented at Transcatheter Cardiovascular Therapeutics, Oct 2005: Washington DC. 60.

Dixon S. Saphenous vein graft protection in a distal embolic protection randomized trial // Presented at Transcatheter Cardiovascular Therapeutics, Oct 2005: Washington DC. 60.

Fischell T. A., Carter A.J., Foster M.T., et al. Reversal of “no reflow” during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn. 1998;45(4): 360—365. 72.

Fischell T.A., Carter A.J., Foster M.T., et al. Reversal of “no reflow” during vein graft stenting using high velocity boluses of intracoronary adenosine // Cathet Cardiovasc Diagn. 1998;45(4): 360-365. 72.

Harskamp R. E., Beijk M. A., Damman P., Tijssen J. G., Lopes R. D. & de Winter R. J. Pre¬hospitalization antiplatelet therapy and outcomes after saphenous vein graft intervention. Am J Cardiol. 2013;111(2):153—158. Epub 2012 Oct 24. 69.

Harskamp R.E., Beijk M.A., Damman P., Tijssen J.G., Lopes R.D., de Winter R.J. Prehospitalization antiplatelet therapy and outcomes after saphenous vein graft intervention // Am J Cardiol. 2013;111(2):153-158. Epub 2012 Oct 24. 69.

10.

Harskamp R. E., Lopes R. D., Baisden C. E., de Winter R. J. & Alexander J. H. Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future direc-tions. Ann Surg. 2013;257(5):824—833. 1.

Harskamp R.E., Lopes R.D., Baisden C.E., de Winter R.J., Alexander J.H. Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions // Ann Surg. 2013;257(5):824-833. 1.

11.

Hillegass W. B., Dean N. A., Lial L., Rhinehart R. G. & Myers P. R. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interven-tions: initial human clinical experience. J Am Coll Cardiol. 2001;37(5):1335—1343. 75.

Hillegass W.B., Dean N.A., Lial L., Rhinehart R.G., Myers P.R. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience // J Am Coll Cardiol. 2001;37(5):1335-1343. 75.

12.

Hong M. K., Mehran R., Dangas G., et al. Creatine kinase-MB enzyme elevation following suc-cessful saphenous vein graft intervention is associated with late mortality. Circulation. 1999;100(24):2400—2405. 9.

Hong M.K., Mehran R., Dangas G., et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality // Circulation. 1999;100(24):2400-2405. 9.

13.

Hong Y. J., Jeong M. H., Ahn Y., et al. Intravascular ultrasound analysis of plaque characteristics and postpercutaneous coronary intervention catheterization outcomes according to the remodeling pattern in narrowed saphenous vein grafts. Am J Cardiol. 2012;110(9):1290—1295. Epub 2012 Jul 25. 14.

Hong YJ, Jeong MH, Ahn Y, et al. Intravascular ultrasound analysis of plaque characteristics and postpercutaneous coronary intervention catheterization outcomes according to the remodeling pattern in narrowed saphenous vein grafts.// Am J Cardiol. 2012;110(9):1290- 1295. Epub 2012 Jul 25. 14.

14.

Hong Y. J., Pichard A. D., Mintz G. S., et al. Outcome of undersized drug-eluting stents for percu-taneous coronary intervention of saphenous vein graft lesions. Am J Cardiol. 2010;105(2):179—185. Epub 2009 Nov 14. 51.

Hong Y.J., Pichard A.D., Mintz G.S., et al. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions // Am J Cardiol. 2010; 105(2):179-185. Epub 2009 Nov 14. 51.

15.

Iakovou I., Dangas G., Mintz G. S., et al. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. Am J Cardiol. 2004;93(8):963—968. 50.

Iakovou I., Dangas G., Mintz G.S., et al. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome // Am J Cardiol. 2004;93(8):963-968. 50.

16.

Kaplan B. M., Benzuly K. H., Kinn J. W., et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardio-vasc Diagn. 1996;39(2):113—118. 78.

Kaplan B.M., Benzuly K.H., Kinn J.W., et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin // Cathet Cardiovasc Diagn. 1996;39(2):113-118. 78.

17.

Kapoor N., Yalamanchili V., Siddiqui T., Raza S., Leesar M. A. Cardioprotective effect of high-dose intragraft adenosine infusion on microvascular function and prevention of no-reflow during saphenous vein grafts intervention. Catheter Cardiovasc Interv. 2014;83(7):1045—1054. Epub 2014 Jan 31. 73.

Kapoor N., Yalamanchili V., Siddiqui T., Raza S., Leesar M.A. Cardioprotective effect of highdose intragraft adenosine infusion on microvascular function and prevention of no-reflow during saphenous vein grafts intervention // Catheter Cardiovasc Interv. 2014;83(7):1045-1054. Epub 2014 Jan 31. 73.

18.

Keeley E. C., Velez C. A. & O’Neill W. W. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Car-diol. 2001;38(3):659—665. 7.

Keeley E.C, Velez C.A., O’Neill W.W. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts // J Am Coll Cardiol. 2001;38(3):659-665. 7.

19.

Kern M. J. Is the coronary physiology of bypass grafts different from that of the native coronary artery? Comment on the “hemodynamic evaluation of coronary artery bypass graft lesions using fractional flow reserve”. Catheter Cardiovasc Interv. 2008;72(4):486—487. 18.

Kern M.J. Is the coronary physiology of bypass grafts different from that of the native coronary artery? Comment on the “hemodynamic evaluation of coronary artery bypass graft lesions using fractional flow reserve” // Catheter Cardiovasc Interv. 2008;72(4):486-487. 18.

20.

Kirtane A. J., Heyman E. R. & Metzger C. Correlates of adverse events during saphenous vein graft intervention with distal embolic protection: a PRIDE substudy. JACC Cardiovasc Interv. 2008;1(2):186—191. 8.

Kirtane A.J., Heyman E.R., Metzger C. Correlates of adverse events during saphenous vein graft intervention with distal embolic protection: a PRIDE substudy // JACC Cardiovasc Interv. 2008;1(2):186-191. 8.

21.

Kitabata H., Loh J. P., Pendyala L. K., et al. Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits. Am J Cardiol. 2013;112(1):61—67. 35.

Kitabata H., Loh J.P., Pendyala L.K., et al. Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits // Am J Cardiol. 2013;112(1):61-67. 35.

22.

Kumar D., Dangas G., Mehran R., et al. Comparison of bivalirudin versus bivalirudin plus glyco-protein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators). Am J Cardiol. 2010;106(7):941—945. 67.

Kumar D., Dangas G., Mehran R., et al. Comparison of bivalirudin versus bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aortocoronary grafts (the ACUITY trial investigators) // Am J Cardiol. 2010;106(7):941-945. 67.

23.

Leborgne L., Cheneau E., Pichard A., et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. Am Heart J. 2003;146(3):501—506. 48.

Leborgne L., Cheneau E., Pichard A., et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft // Am Heart J. 2003;146(3):501-506. 48.

24.

Levine G. N., Bates E. R., Blankenship J. C., et al. 2011 ACCF/AHA/SCAI guideline for per¬cutaneous coronary intervention. A report of the American College of Cardiology Foundation. American Heart Association Task Force on Practice Guidelines and the Society for Car¬diovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44—e122. Epub 2011 Nov 7. 68.

Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions // J Am Coll Cardiol. 2011;58(24):e44-e122. Epub 2011 Nov 7. 68.

25.

Maluenda G., Alfonso F. & Pichard A. D. Percutaneous intervention of a thrombotic-occluded saphenous vein graft successfully treated using the undersized stent approach to prevent distal em-bolization. Catheter Cardiovasc Interv. 2011;78(1):65—69. Epub 2011 Feb 16. 52.

Maluenda G., Alfonso F., Pichard A.D. Percutaneous intervention of a thrombotic-occluded saphenous vein graft successfully treated using the undersized stent approach to prevent distal embolization // Catheter Cardiovasc Interv. 2011;78(1):65-69. Epub 2011 Feb 16. 52.

26.

Mehilli J., Pache J., Abdel-Wahab M., et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomized controlled superiority trial. Lancet. 2011;378(9796):1071—1078. 30.

Mehilli J., Pache J., Abdel-Wahab M., et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomized controlled superiority trial // Lancet. 2011; 378(9796):1071-1078. 30.

27.

Mehta S. K., Frutkin A. D., Milford-Beland S., et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Car-diology-National Cardiovascular Data Registry). Am J Cardiol. 2007;100(7):1114—1118. Epub 2007 Jul 18. 53.

Mehta S.K., Frutkin A.D., Milford-Beland S., et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry) // Am J Cardiol. 2007;100(7):1114- 1118. Epub 2007 Jul 18. 53.

28.

Michaels A. D., Appleby M., Otten M. H., et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol. 2002;14(6): 299—302. 76.

Michaels A.D., Appleby M., Otten M.H., et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial // J Invasive Cardiol. 2002; 14(6):299-302. 76.

29.

Murphy G. J. & Angelini G. D. Insights into the pathogenesis of vein graft disease: lessons from intravascular ultrasound. Cardiovasc Ultrasound. 2004;2:8. 15.

Murphy G.J., Angelini G.D. Insights into the pathogenesis of vein graft disease: lessons from intravascular ultrasound // Cardiovasc Ultrasound. 2004;2:8. 15.

30.

Naidu S. S., Turco M. A. & Mauri L. Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy). Am J Cardiol. 2010;105(8):1060—1064. Epub 2010 Feb 20. 10.

Naidu S.S., Turco M.A., Mauri L. Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy) // Am J Cardiol. 2010;105(8):1060-1064. Epub 2010 Feb 20. 10.

31.

Okabe T., Lindsay J., Torguson R., et al. Can direct stenting in selected saphenous vein graft le-sions be considered an alternative to percutaneous intervention with a distal protection device? Catheter Cardiovasc Interv. 2008;72(6):799—803. 49.

Okabe T., Lindsay J., Torguson R., et al. Can direct stenting in selected saphenous vein graft lesions be considered an alternative to percutaneous intervention with a distal protection device? // Catheter Cardiovasc Interv. 2008;72(6):799-803. 49.

32.

Roffi M., Mukherjee D., Chew D. P., et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aorto¬coronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002; 106(24):3063—3067. 66.

Roffi M., Mukherjee D., Chew D.P., et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials // Circulation. 2002;106(24):3063-3067. 66.

33.

Sdringola S., Assali A., Ghani M., et al. Adenosine use during aortocoronary vein graft interven-tions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51(4):394—399. 71.

Sdringola S., Assali A., Ghani M., et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon // Catheter Cardiovasc Interv. 2000;51(4):394-399. 71.

34.

Sdringola S., Assali A. R., Ghani M., et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv. 2001;54(3): 318—324. 70.

Sdringola S., Assali A.R., Ghani M., et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention // Catheter Cardiovasc Interv. 2001; 54(3):318-324. 70.

35.

Sharma S. Intra-graft abciximab and verapamil combined with direct stenting is a safe and effec-tive strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus. Recent Pat Cardiovasc Drug Discov. 2012;7(2):152—159. 77.

Sharma S. Intra-graft abciximab and verapamil combined with direct stenting is a safe and effective strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus // Recent Pat Cardiovasc Drug Discov. 2012;7(2):152-159. 77.

36.

Stone G. W., Rogers C., Hermiller J., et al. Randomized comparison of distal protection with a fil-ter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003;108(5): 548—553. 58.

Stone G.W., Rogers C., Hermiller J., et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts // Circulation. 2003;108(5): 548-553. 58.

37.

Sturm E., Goldberg D. & Goldberg S. Stenting in saphenous vein grafts with distal protection us-ing a second generation filter-based catheter: the combined BLAZE I and II registries. Presented at Transcatheter Cardiovascular Therapeutics, Oct 2005: Washington DC. 59.

Sturm E., Goldberg D., Goldberg S. Stenting in saphenous vein grafts with distal protection using a second generation filter-based catheter: the combined BLAZE I and II registries // Presented at Transcatheter Cardiovascular Therapeutics, Oct 2005: Washington DC. 59.

38.

Zoghbi G. J., Goyal M., Hage F., et al. Pretreatment with nitroprusside for microcirculatory pro-tection in saphenous vein graft interventions. J Invasive Cardiol. 2009;21(2):34—39. 74.

Zoghbi G.J., Goyal M., Hage F., et al. Pretreatment with nitroprusside for microcirculatory protection in saphenous vein graft interventions // J Invasive Cardiol. 2009;21(2):34-39. 74.